|Bid||64.63 x 800|
|Ask||80.07 x 1000|
|Day's Range||78.31 - 80.31|
|52 Week Range||40.20 - 81.35|
|Beta (5Y Monthly)||1.82|
|PE Ratio (TTM)||43.71|
|Earnings Date||Apr 29, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||86.36|
MORRISVILLE, N.C., April 01, 2021 (GLOBE NEWSWIRE) -- Syneos Health® (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization, will release its first quarter 2021 financial results on Thursday, April 29, 2021, prior to its earnings call at 8:00 a.m. ET. Participants may access the conference call live via webcast on the Investor Relations section of the Syneos Health website at investor.syneoshealth.com. To participate via telephone, please register in advance at this link. Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique passcode and registrant ID that can be used to access the call. A webcast replay will be available on the Investor Relations section of the Syneos Health website at investor.syneoshealth.com after 1:00 p.m. on April 29, 2021. About Syneos HealthSyneos Health® (Nasdaq:SYNH) is the only fully integrated biopharmaceutical solutions organization. The Company, including a Contract Research Organization (CRO) and Contract Commercial Organization (CCO), is purpose-built to accelerate customer performance to address modern market realities. We bring together approximately 25,000 clinical and commercial minds with the ability to support customers in more than 110 countries. Together we share insights, use the latest technologies and apply advanced business practices to speed our customers’ delivery of important therapies to patients. To learn more about how we are Shortening the distance from lab to life®, visit syneoshealth.com or subscribe to our podcast. Investor Relations Contact:Ronnie SpeightSenior Vice President, Investor Relations+1 919 745 2745Investor.Relations@syneoshealth.com Press/Media Contact:Gary GatyasExecutive Director, External Communications+1 908 763 email@example.com
Investors continue to be optimistic about Syneos Health (SYNH) on solid sequential recovery of its operating segments and strategic partnerships.
Syneos Health (SYNH) new partnership will extend the company's mission to boost research and enable universal patient and provider access with clinical research services.